Part 3/9:
Investigating the Roots of Treatment Resistance
The phenomenon of treatment-resistant depression (TRD) has prompted researchers to explore underlying causes and alternative solutions. Dr. Elo notes that ongoing research over recent years has focused on understanding why certain individuals do not respond to first-line treatments. Some hypotheses involve neurobiological differences, genetic factors, or dysregulation in brain circuits involved in mood regulation.
Exploring Novel Therapies: Ketamine and Psychedelics
In response to the challenge of TRD, research institutions like Rush have initiated trials examining innovative treatments such as ketamine and psychedelic substances, including psilocybin, the active compound in "magic mushrooms."